Published: Jul, 2019
Healthcare scientists, researchers, and practitioners are under constantly pressure to reinvent current medical practices to improve treatment and diagnosis. This factor has always kept the medical fraternity on its toes, and has often led to improvements in generic treatment mechanisms for common diseases and disorder. Healthcare resource utilization studies suggest the US Healthcare industry is majorly affected by the heavy incidence of refractory myasthenia gravis. Not only does the high incidence of this disease affect research practices, but also poses a question on the development of effective treatment lines.
The healthcare and medical industries are held severely accountable in the case of chronic and untreatable diseases. For this reason, medical practitioners are going an extra mile to manage chronic diseases related to muscular pain. Considering the factors mentioned above, it is legit to prognosticate that the global myasthenia gravis market would trace a lucrative growth trajectory. Furthermore, intense research in the field of pain management could also play an instrumental role in market growth.
Several research studies point to the frustration and mental trauma felt by patients suffering from disorders that hamper normal movements. This factor, coupled with increased investments in medical research, has created increased demand within the global myasthenia gravis market.
Transparency Market Research (TMR) predicts that the global myasthenia gravis market would earn revenues worth US$2,313.1 mn by 2025, rising up from a value of US$975.1 mn in 2016. The CAGR of the global myasthenia gravis market for the period between 2017 and 2025 is calculated to be 10.10%. The changing tendencies of the masses towards disorders that affect their appearance has contributed towards market growth.
Ophthalmologic Care Gathers Traction
The growing cases of swollen eyes as a result of myasthenia gravis has played a major role in market growth. Ophthalmologists are frequented by several people suffering from myasthenia gravis, and the responsiveness of the former towards ailing patients has aided market growth. Furthermore, robust intra-domain connections with the field of healthcare has made it easy for ophthalmologists to take the help of other specialists. This factor has also generated huge-scale market demand.
Special Facilities for the Elderly
The growing geriatric population has generated a sense of accountability and conscientiousness across the medical fraternity. Medical practitioners and experts have developed a system to prioritise treatment of the elderly. This factor has played a vital role in propelling demand within the global myasthenia gravis market in recent times. Troubles in walking associated with myasthenia gravis are deftly managed through inbound and outbound medical treatments.
North America to Witness Sturdy Growth
On the basis of geography, the global myasthenia gravis market has been segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. The myasthenia gravis market in North America is slated to grow as medical practitioners join hand with the medical research fraternity to manage patients with myasthenia gravis. The regional market has also excavated the perks of hosting the most renowned medical research institutions.
Vendors to Focus on Pain Management Hacks
The market players in the global myasthenia gravis market are focusing on developing management hacks rather than treatment lines for the disease. Some of the leading players in the global myasthenia gravis market are Takeda Pharmaceutical Company Limited, Avadel Pharmaceuticals plc, Alexion Pharmaceutical Inc., CSL Behring, Baxter International Inc., Grifols S.A., Shire plc, F. Hoffmann-La Roche AG, Novartis AG, and Valeant Pharmaceuticals International Inc.
The review is based on TMR’s report titled, “Myasthenia Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators) and Rapid Immunotherapies (Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025”.
The global myasthenia gravis market is segmented as follows:
Global Myasthenia Gravis Market, by Treatment
- Drug Treatment
- Cholinesterase Inhibitors
- Chronic Immunomodulators
- Monoclonal Antibodies
- Rapid Immunotherapies
- Intravenous Immunoglobulin (Ivlg)
Global Myasthenia Gravis Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453